Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-07994525 IN PARTICIPANTS WITH ADVANCED MALIGNANCIES
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor …
Advanced MalignanciesAdvanced Cancer
Estimated
~$10 – $7,500
PfizerNCT07426757
Phase 1
A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants Who Were Previously Treated for Advanced Malignancies
The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor a…
Advanced Malignancies
Estimated
~$10 – $8,750
PharmaMarNCT07644039
Phase 3
An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indicati…
Hematologic MalignancySolid TumorAdvanced Malignancies
Estimated
~$10 – $8,750
Novartis PharmaceuticalsNCT06401356
Phase 1
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced …
Advanced MalignanciesOvarian CancerT-cell Lymphoma+1 more
Estimated
~$10 – $7,500
BioInvent International ABNCT04752826